MXPA04000889A - Formas cristalinas vi y vii de atorvastatina calcica. - Google Patents

Formas cristalinas vi y vii de atorvastatina calcica.

Info

Publication number
MXPA04000889A
MXPA04000889A MXPA04000889A MXPA04000889A MXPA04000889A MX PA04000889 A MXPA04000889 A MX PA04000889A MX PA04000889 A MXPA04000889 A MX PA04000889A MX PA04000889 A MXPA04000889 A MX PA04000889A MX PA04000889 A MXPA04000889 A MX PA04000889A
Authority
MX
Mexico
Prior art keywords
vii
crystalline forms
atorvastatin calcium
methods
relates
Prior art date
Application number
MXPA04000889A
Other languages
English (en)
Spanish (es)
Inventor
Satyanarayana Reddy M
Original Assignee
Reddys Lab Ltd Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reddys Lab Ltd Dr filed Critical Reddys Lab Ltd Dr
Publication of MXPA04000889A publication Critical patent/MXPA04000889A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MXPA04000889A 2001-07-30 2002-01-07 Formas cristalinas vi y vii de atorvastatina calcica. MXPA04000889A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN620MA2001 2001-07-30
PCT/US2002/000431 WO2003011826A1 (en) 2001-07-30 2002-01-07 Crystalline forms vi and vii of atorvastatin calcium

Publications (1)

Publication Number Publication Date
MXPA04000889A true MXPA04000889A (es) 2004-06-03

Family

ID=35160889

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04000889A MXPA04000889A (es) 2001-07-30 2002-01-07 Formas cristalinas vi y vii de atorvastatina calcica.

Country Status (19)

Country Link
EP (2) EP2292600A1 (enExample)
JP (1) JP2005500351A (enExample)
KR (1) KR20040019043A (enExample)
CN (1) CN100471836C (enExample)
AU (1) AU2002255479B2 (enExample)
BG (1) BG108518A (enExample)
BR (1) BR0211488A (enExample)
CA (1) CA2454500C (enExample)
CZ (1) CZ2004126A3 (enExample)
EE (1) EE200400048A (enExample)
HR (1) HRP20040077A2 (enExample)
IL (2) IL159626A0 (enExample)
MX (1) MXPA04000889A (enExample)
NO (1) NO20040390L (enExample)
NZ (1) NZ530785A (enExample)
PL (1) PL368647A1 (enExample)
RU (1) RU2304139C2 (enExample)
WO (1) WO2003011826A1 (enExample)
ZA (1) ZA200400573B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
PL362472A1 (en) * 2000-11-03 2004-11-02 Teva Pharma Atorvastatin hemi-calcium form vii
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
KR100790766B1 (ko) * 2000-12-27 2008-01-03 테바 파마슈티컬 인더스트리즈 리미티드 아토르바스타틴의 결정 형태, 이의 제조방법 및 이를 포함하는 약제학적 조성물
WO2003070702A1 (en) * 2002-02-15 2003-08-28 Teva Pharmaceutical Industries Ltd. Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix
IL163594A0 (en) 2002-02-19 2005-12-18 Teva Pharma Processes for desolvating solvates of atorvastatinhemi-calcium and atorvastatin hemi-calcium essentially free of organic solvent
EP1424324A1 (en) * 2002-11-28 2004-06-02 Teva Pharmaceutical Industries Limited Crystalline form F of Atorvastatin hemi-calcium salt
CA2508871C (en) * 2002-11-28 2008-09-09 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
SI1727795T1 (sl) 2004-03-17 2012-05-31 Ranbaxy Lab Ltd Postopek za pripravo atorvastatin kalcija v amorfni obliki
WO2005090301A1 (en) * 2004-03-17 2005-09-29 Ranbaxy Laboratories Limited Crystalline form of atorvastatin hemi calcium
RU2412191C2 (ru) * 2004-07-16 2011-02-20 Лек Фармасьютиклз Д.Д. Продукты окислительной деструкции кальций аторвастатина
MX2007000765A (es) * 2004-07-20 2007-03-28 Warner Lambert Co Formas cristalinas de sal de calcio del acido (r-(r*, r*))-2- (4-fluorofenil)- beta,gama- dihidroxi-5- (1-metiletil)-3 -fenil-4-((fenilamino) (carbonil)-1ih -pirrol-1- heptanoico (2:1).
EP1694685A1 (en) 2004-09-28 2006-08-30 Teva Pharmaceutical Industries Ltd Process for preparing forms of atorvastatin calcium substantially free of impurities
KR20070067175A (ko) 2004-10-28 2007-06-27 워너-램버트 캄파니 엘엘씨 무정형 아토르바스타틴 형성 방법
WO2006048894A1 (en) * 2004-11-05 2006-05-11 Morepen Laboratories Limited Novel crystalline forms of atorvastatin calcium and processes for preparing them.
MX2007014329A (es) * 2005-12-13 2008-03-19 Teva Pharma Forma cristalina de hemi-calcio de atorvastatina y procesos para la preparacion de ella.
EP2185527A2 (en) * 2007-07-11 2010-05-19 Actavis Group PTC EHF Novel polymorph of atorvastatin calcium and use thereof for the preparation of amorphous atorvastatin calcium
KR20120011249A (ko) 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
CN104983702A (zh) * 2015-07-23 2015-10-21 青岛蓝盛洋医药生物科技有限责任公司 一种治疗高胆固醇血症的药物阿托伐他汀钙组合物片剂
CN108157405B (zh) * 2018-02-06 2020-10-02 上海应用技术大学 一种灭蟑螂饵剂及其制备方法和应用
WO2025147589A1 (en) 2024-01-05 2025-07-10 Osanni Bio, Inc. Implants, compositions, and methods for treating retinal diseases and disorders

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
IL109570A0 (en) * 1993-05-17 1994-08-26 Fujisawa Pharmaceutical Co Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
DE69634054T2 (de) * 1995-07-17 2005-12-08 Warner-Lambert Co. Kristalline (R-(R*, R*))-2-(4-Fluorophenyl)-β, δ-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-((Phenylamino)Carbonyl)-1H-Pyrrol-1-Heptancarbonsäure Hemi Calcium Salz (Atorvastatin)
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
US6087511A (en) 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
US5929156A (en) 1997-05-02 1999-07-27 J.M. Huber Corporation Silica product for use in elastomers
HU226640B1 (en) 1999-10-18 2009-05-28 Egis Gyogyszergyar Nyilvanosan Process for producing amorphous atorvastatin calcium salt
SI1535613T1 (sl) 1999-11-17 2010-12-31 Teva Pharma Postopek za pripravo polimorfne oblike atorvastatin kalcija
PL362472A1 (en) * 2000-11-03 2004-11-02 Teva Pharma Atorvastatin hemi-calcium form vii
IL155890A0 (en) * 2000-11-16 2003-12-23 Teva Pharma HYDROLYSIS OF [R(R*,R*)]-2-(4-FLUOROPHENYL)-beta,delta-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID ESTERS WITH CALCIUM HYDROXIDE
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
KR100790766B1 (ko) * 2000-12-27 2008-01-03 테바 파마슈티컬 인더스트리즈 리미티드 아토르바스타틴의 결정 형태, 이의 제조방법 및 이를 포함하는 약제학적 조성물
WO2002057229A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)

Also Published As

Publication number Publication date
IL159626A0 (en) 2004-06-01
CN100471836C (zh) 2009-03-25
CA2454500A1 (en) 2003-02-13
NZ530785A (en) 2005-10-28
JP2005500351A (ja) 2005-01-06
EP2292600A1 (en) 2011-03-09
RU2004103470A (ru) 2005-06-20
RU2304139C2 (ru) 2007-08-10
IL159626A (en) 2013-04-30
BR0211488A (pt) 2004-08-17
EP1414796A1 (en) 2004-05-06
WO2003011826A1 (en) 2003-02-13
HRP20040077A2 (en) 2004-06-30
AU2002255479B2 (en) 2008-09-11
CA2454500C (en) 2009-11-10
BG108518A (en) 2004-08-31
KR20040019043A (ko) 2004-03-04
CZ2004126A3 (cs) 2004-12-15
ZA200400573B (en) 2005-05-11
EE200400048A (et) 2004-04-15
CN1537098A (zh) 2004-10-13
NO20040390L (no) 2004-01-29
PL368647A1 (en) 2005-04-04

Similar Documents

Publication Publication Date Title
MXPA04000889A (es) Formas cristalinas vi y vii de atorvastatina calcica.
TWI319396B (en) Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
EP1783113A3 (en) Crystal form VII of atorvastatin hemi-calcium
ZA966043B (en) Novel process for the production of amorphous [R-(R*,R*)]-2(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acide calcium salt (2:1).
BR0116785A (pt) Processo para a sìntese da forma v de atorvastatina e fenilboronatos como compostos intermediários
YU56803A (sh) Pripremanje nekristalinskog atorvastatin-kalcijuma
PL324496A1 (en) Crystalline fsemi-calcinous salt of [r-(r*,r*)]-2-(4-fluorophenyl)-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrolo-1-enantanic acid (atorvastatin)
PL377555A1 (pl) Nowe krystaliczne postaci soli hemi-wapniowej atorwastatyny i sposoby ich wytwarzania oraz nowe sposoby wytwarzania innych postaci
AU2000254249A1 (en) Synthesis of (r-(r*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-
EP1480950A4 (en) NOVEL HEMI-CALCIUM CRYSTALLINE FORMS OF ATORVASTATIN AND METHODS FOR THEIR PREPARATION, AS WELL AS NEW METHODS FOR THE PREPARATION OF FORORVASTATIN HEMI-CALCIUM FORMS I, VIII AND IX
PL370061A1 (en) Crystalline (r-(r*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-heptanoic acid calcium salt (2:1)
CA2508871A1 (en) Crystalline form f of atorvastatin hemi-calcium salt
WO2005105738A3 (en) Salt forms of atorvastatin
IL173651A0 (en) Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
ZA200303974B (en) Hydrolysis of [R(R*,R*)]-2-(4-Fluorophenyl)-b,D-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-[(Phenylamino)Carbonyl]-1H-Pyrrole-1-Heptanoic acid esters with calcium hydroxide.
SI0848704T1 (en) Form iii crystalline (r-(r*,r*))-2-(4-fluorophenyl)-beta-delta-dihydroxy-5-(1-methyl-ethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
PL349307A1 (en) Novel crystalline form of semi-calcium [r-(r ,r)]-2-(4-fluorophenyl)-beta, dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl)-1h-pyrrole-1-heptanic salt (athorovastatin), method of obtaining same, pharmacological composition containing such salt and medical application thereof
LT2004018A (en) Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
AU2001234058A1 (en) Form v crystalline (r-(r*,r*))-2-(4-fluorophenyl)-ss,$g(d)-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1- heptanoic acid hemi calcium salt. (atorvastatin)
HK1060294A (en) Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
MXPA00012407A (es) Nuevo compuesto pirrol sustituido.
HK1056556A (en) HYDROLYSIS OF [R(R*,R*)]-2-(4-FLUOROPHENYL)-β, δ-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID ESTERS WITH CALCIUM HYDROXIDE
PL1957452T3 (pl) "Nowe postacie soli magnezowej kwasu [R-(R*,R*)]-2-(4-fluorofenylo)-ß,δ-dihydroksy-5-(1-metyloetylo)-3-fenylo-4-[(fenylamino)karbonylo]-1H-pirolo-1-heptanowego"

Legal Events

Date Code Title Description
FG Grant or registration